Yttrium-90-EDTMP: A radiotherapeutic agent in the treatment of leukaemias

A. A. Keeling, Andrew T M Vaughan, R. P. Beaney

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

Yttrium-90 chelated by the tetraphosphonate EDTMP achieved a high uptake in bone and a rapid clearance from all soft tissues compared with 90Y nitrilotriacetate, citrate and acetate. The biological half-life of 90Y in the bone was greater than 72 h, but the quantity, and therefore dose, could be reduced by 50% using repeated, non-toxic chelation therapy with the calcium salt of DTPA. This treatment should be able to supplement current treatments for leukaemia where the dose of external beam radiation is associated with considerable morbidity.

Original languageEnglish (US)
Pages (from-to)74-78
Number of pages5
JournalBritish Journal of Cancer
Volume60
Issue number1
StatePublished - 1989
Externally publishedYes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Yttrium-90-EDTMP: A radiotherapeutic agent in the treatment of leukaemias'. Together they form a unique fingerprint.

  • Cite this